Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RFS 2000 (9-Nitro-camptothecin) in Advanced Ovarian Cancer
NCT00006230Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- May 2000
- Primary completion
- Apr 2003
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial of rubitecan in ovarian cancer, sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoints: Objective Response Rate, Duration of Response and 1 more. Started May 2000; status: completed.
02
Drugs
rubitecan
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT00006230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006230.